Oragenics Inc. [AMEX: OGEN] plunged by $0.0 during the normal trading session on Tuesday and reaching a high of $0.44 during the day while it closed the day at $0.43. The company report on November 24, 2020 that Oragenics Announces Closing of $6.0 Million Underwritten Public Offering.
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced, the closing of its previously announced underwritten public offering of 14,189,189 shares of common stock at a price to the public of $0.37 per share.
Oragenics expects to receive gross proceeds of approximately $6.0 million from the offering.
Oragenics Inc. stock has also loss -5.16% of its value over the past 7 days. However, OGEN stock has declined by -39.75% in the 3 months of the year. Over the past six months meanwhile, it has lost -20.16% and lost -17.40% year-on date.
The market cap for OGEN stock reached $27.66 million, with 59.67 million shares outstanding and 56.76 million shares in the current float. Compared to the average trading volume of 4.88M shares, OGEN reached a trading volume of 4234716 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Oragenics Inc. [OGEN]:
The Average True Range (ATR) for Oragenics Inc. is set at 0.04 The Price to Book ratio for the last quarter was 10.80, with the Price to Cash per share for the same quarter was set at 0.16.
OGEN stock trade performance evaluation
Oragenics Inc. [OGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.16. With this latest performance, OGEN shares dropped by -8.86% in over the last four-week period, additionally sinking by -20.16% over the last 6 months – not to mention a drop of -15.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OGEN stock in for the last two-week period is set at 43.67, with the RSI for the last a single of trading hit 43.60, and the three-weeks RSI is set at 42.97 for Oragenics Inc. [OGEN]. The present Moving Average for the last 50 days of trading for this stock 0.4923, while it was recorded at 0.4388 for the last single week of trading, and 0.6456 for the last 200 days.
Oragenics Inc. [OGEN]: An insightful look at the core fundamentals
Return on Total Capital for OGEN is now -80.98, given the latest momentum, and Return on Invested Capital for the company is -80.27. Return on Equity for this stock declined to -81.68, with Return on Assets sitting at -74.47. When it comes to the capital structure of this company, Oragenics Inc. [OGEN] has a Total Debt to Total Equity ratio set at 5.69. Additionally, OGEN Total Debt to Total Capital is recorded at 5.38, with Total Debt to Total Assets ending up at 4.96. Long-Term Debt to Equity for the company is recorded at 6.26, with the Long-Term Debt to Total Capital now at 3.68.
Reflecting on the efficiency of the workforce at the company, Oragenics Inc. [OGEN] managed to generate an average of -$2,223,715 per employee.Oragenics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.60 and a Current Ratio set at 9.60.
Earnings per share (EPS) analysis for Oragenics Inc. [OGEN] stock
With the latest financial reports released by the company, Oragenics Inc. posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 20.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OGEN.
Oragenics Inc. [OGEN]: Insider Ownership positions
There are presently around $4 million, or 17.30% of OGEN stock, in the hands of institutional investors. The top three institutional holders of OGEN stocks are: THIRD SECURITY, LLC with ownership of 4,612,166, which is approximately 0% of the company’s market cap and around 7.40% of the total institutional ownership; VANGUARD GROUP INC, holding 1,422,482 shares of the stock with an approximate value of $0.61 million in OGEN stocks shares; and SARA-BAY FINANCIAL, currently with $0.57 million in OGEN stock with ownership of nearly -0.227% of the company’s market capitalization.
Positions in Oragenics Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 9 institutional holders increased their position in Oragenics Inc. [AMEX:OGEN] by around 1,263,469 shares. Additionally, 10 investors decreased positions by around 145,191 shares, while 9 investors held positions by with 8,451,968 shares. The mentioned changes placed institutional holdings at 9,860,628 shares, according to the latest SEC report filing. OGEN stock had 5 new institutional investments in for a total of 395,905 shares, while 7 institutional investors sold positions of 112,790 shares during the same period.